InvestorsObserver
Sign Up Login

ADMA Adma Biologics

$1.45 $0.00 (0.00%)
Add to Watchlist Compare
Overall

ADMA Stock Analysis Overview

What this means: Adma Biologics (ADMA) gets an Overall Rank of 50, which is an above average rank under InvestorsObserver's stock ranking system. Our system considers the available information about the company and then compares it to all the other stocks we have data on to get a percentile-ranked value. ADMA's 50 means that it ranks higher than 50% of stocks.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

View Sample Report
Fundamental PREMIUM

ADMA Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

Short-Term Technical PREMIUM

ADMA Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

Long-Term Technical PREMIUM

ADMA Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

Analyst Ranking PREMIUM

ADMA Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

Valuation PREMIUM

ADMA Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

Stock Sentiment PREMIUM

ADMA Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

ADMA Stock Analysis Overview

What this means: Adma Biologics (ADMA) gets an Overall Rank of 50, which is an above average rank under InvestorsObserver's stock ranking system. Our system considers the available information about the company and then compares it to all the other stocks we have data on to get a percentile-ranked value. ADMA's 50 means that it ranks higher than 50% of stocks.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

Create a FREE account to see full ADMA report

ADMA Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

ADMA Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

ADMA Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

ADMA Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

ADMA Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

ADMA Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

Adma Biologics (ADMA) Analyst Forecast

ADMA Price, Volume, Earnings, and Dividend Date

  • Last Price $1.45
  • Previous Close $1.45
  • Change $0.00
  • Open $1.43
  • Volume 1,895,100
  • Avg. Volume (100-day) 2,773,041
  • Market Cap 283,930,035
  • Days Range 1.38 - 1.47
  • 52-week Range 1.01 - 3.11
  • Dividend Yield —
  • Ex. Dividend Date —
  • P-E —
  • EPS —
  • Earnings Date 02/08/22
  • Sector Healthcare
  • Industry Biotechnology
  • Avg. Analyst Rec. Premium
  • Beta 0.806
  • PEG Ratio —

Adma Biologics (ADMA) Company Description

ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. Its targeted patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disorder or who may be immune-suppressed for medical reasons. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipate providing contract filling, labeling and packing services.

Adma Biologics (ADMA) Stock Chart

View Interactive ADMA chart

My Watchlists

Follow Your Favorite Stocks

Top Stocks in Biotechnology

Company Price
Genfit S.A. ADR (GNFT) (GNFT) $4.47
Verona Pharma Plc ADR (VRNA) (VRNA) $6.37
Tricida Inc (TCDA) (TCDA) $8.81
Fireman B.V. (IFRX) (IFRX) $3.52
Opiant Pharmaceuticals Inc (OPNT) (OPNT) $25.64
Crinetics Pharmaceuticals Inc (CRNX) (CRNX) $18.97
Bellus Health Inc (BLU) (BLU) $5.56
Regeneron Pharmaceuticals (REGN) (REGN) $621.40
Viridian Therapeutics Inc (VRDN) (VRDN) $17.49
Liquidia Corp (LQDA) (LQDA) $5.50